Researchers can now discover the solanezumab phase 3 data through the AD Workbench and submit access requests through interoperability with the Vivli platform. Once researchers have received permissioned access, they can bring the data to secure cloud-based workspaces on the AD Workbench for analysis using free tools compute, and storage provided by the AD Data Initiative.

Collaborations like these are a milestone in breaking down silos to accelerate critical discoveries in Alzheimer’s and related dementias research.

Explore the AD Workbench.